Preliminary results of a Phase II study: combined systemic polychemotherapy and intrathecal treatment with liposomal cytarabine in patients with primary CNS lymphoma ≥60 years
A Jürgens, H Pels, M Reiser, A Engert, U Herrlinger, M Lamprecht, G Egerer, M Vogt-Schaden, P Hau, G Schackert, H Reichmann, F Kroschinsky, IGH Schmidt-Wolf, U Schlegel · Aktuelle Neurologie · 2009 · Heft 10
Bibliografische Angaben
Zusammenfassung
Objectives: To evaluate response rate, event free survival, overall survival, and toxicity in primary central nervous system lymphoma (PCNSL) after a combined systemic and intrathecal chemotherapy in patients ≥60 years. Patients and methods: From 11/2005 to 03/2009, 70 patients with PCNSL (median age 67 years) were enrolled in phase II study evaluating systemic polychemotherapy combined with intrathecal application of liposomal cytarabine. All patients were 60 years of age or older at time of diagnosis. A high-dose methotrexate (MTX) (cycles 1,2,4,5) and cytarabine (ara-C) (cycles 3,6) based systemic therapy (in…
